REQUIRES LOGIN

    Stay Connected AMCP Facebook Page  AMCP Twitter Page  Linkedin 

    Corporate Member Roster

    Scott Shuster
    Managed Care Marketing
    (847) 938-4840
    scott.shuster@abbvie.com

    Abbott Laboratories is a leading health care innovator, dedicated to improving the lives of people around the world through medical science. Abbott discovers, develops, manufactures and markets high-quality products that span the health-care spectrum from prevention, to diagnosis, to therapy through Abbott's core businesses of pharmaceutical, nutritional, diagnostic, and hospital products.

    Acorda Therapeutics, Inc. http://www.acorda.com
    Steven Sandor
    Vice President, Market Access
    (914) 326-5373
    ssandor@acorda.com

    Acorda Therapeutics is a biotechnology company developing therapies for spinal cord injury, multiple sclerosis and related nervous system disorders. The Company's marketed products include Zanaflex Capsules® (tizanidine hydrochloride), a short-acting drug for the management of spasticity. Acorda filed a New Drug Application (NDA) for its lead clinical product, Fampridine-SR, on January 30, 2009. Clinical trials of Fampridine-SR evaluated its safety and efficacy in improving walking ability in people with MS. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain.

    Alcon Laboratories, Inc. http://www.alconlabs.com
    Dale R. Seibt
    Director, Managed Care Sales
    (817) 568-6064
    dale.seibt@alcon.com

    As the global leader in eye care, Alcon’s mission is to provide innovative products that enhance quality of life by helping people see better. Alcon offers the widest spectrum of eye care products in surgical, pharmaceutical and vision care across 180 markets and operations in 75 countries. Alcon is committed to making significant contributions to preserve, restore and enhance vision by addressing the world’s most pressing eye care needs in areas, such as cataracts, glaucoma, retinal diseases, refractive errors, ocular allergies, dry eye, infection and inflammation. For more information on Alcon, visit www.alcon.com

    Mark Stephan
    Senior National Managed Markets Director
    (267) 424-4270
    Mark.Stephan@alkermes.com

    Alkermes is a fully integrated biopharmaceutical company that applies its scientific expertise and technological know-how to develop innovative medicines designed to yield better therapeutic outcomes for patients with central nervous system (CNS) disorders, including addiction, schizophrenia and depression.

    H. Thomas Knox
    Vice President - U.S. Managed Markets & Government Affairs
    (714) 246-6530
    knox_tom@allergan.com

    Allergan, Inc., with headquarters in Irvine, California, is a global specialty pharmaceutical company that develops and commercializes innovative products for the eye care, neuromodulator, skin care, obesity and other specialty markets. In addition to its discovery-to-development research programs, Allergan has global marketing and sales capabilities in over 100 countries that deliver value to our customers, satisfy unmet medical needs and improve people’s lives. Driven by technology and innovation, Allergan addresses the needs of consumers across the world with over 8,000 employees worldwide, 4 world-class Research and Development facilities and 5 state-of-the-art manufacturing plants.

    Amarin Pharma, Inc. http://www.amarincorp.com
    Joseph Gilhooly
    Senior Director, Managed Care
    (908) 719-1315 x522
    joseph.gilhooly@amarincorp.com

    Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin’s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Vascepa® (icosapent ethyl), Amarin’s first FDA approved product, is a patented, ultra pure omega-3 fatty acid product comprising not less than 96% EPA.

    Brian Brousseau
    Director, Payer Segment Marketing
    (805) 447-4245
    bbrousse@amgen.com

    The world’s largest biotechnology company, Amgen Inc. discovers, develops, and delivers important human therapeutics based on advances in cellular and molecular biology including EPOGEN® (Epoetin alfa), Aranesp® (darbepoetin alfa), NEUPOGEN® (Filgrastim), Neulasta® (pegfilgrastim), Enbrel® (etanercept), Kineret® (anakinra) and Sensipar® (cinacalcet HCl). Amgen’s dedication to science and innovation is driven by a commitment to serving patients.

    Apotex Corporation http://www.apotexcorp.com
    James Van Lieshout
    VP, Market Access
    (303) 444-9102
    jvanlies@apotex.com

    Apotex Inc. was founded in 1974, and is the largest Canadian-owned pharmaceutical company. From its 2 employees, 5,000 square foot beginning, the company has grown to employ over 10,000 people in research, development, manufacturing and distribution facilities world-wide. The Canadian operations of the Apotex Group of Companies has approximately 5,500 employees. Extensive investments in Canadian facilities include over 3 million square feet in manufacturing and R&D facilities in Richmond Hill, Toronto, Etobicoke, Brantford, Windsor and Winnipeg. Apotex produces more than 300 generic pharmaceuticals in approximately 4,000 dosages and formats which, in Canada, are used to fill over 89 million prescriptions a year - the largest amount of any pharmaceutical company in this country

    Argus Health Systems, Inc. http://www.argushealth.com
    Kristy Cayot
    Marketing Manager
    (816) 843-5832
    kristy.cayot@argushealth.com

    Argus Health Systems, Inc., is the leading independent provider of health care information management services supporting commercial, Medicaid and Medicare Part D. Argus serves a wide range of clients and key health care organizations including managed care organizations, pharmacy benefit managers and pharmaceutical manufacturers. Argus was established in 1983, and by 1986 was a pioneer in electronic claims processing. Since then Argus has grown to become one of the largest pharmacy claims processors in the industry. In 2012, Argus processed more than 550 million claims, including one in five of all Medicare Part D claims nationwide. Argus is a wholly-owned subsidiary of DST Systems, Inc., headquartered in Kansas City, Mo. We also have customer relationships in every state in the country. Argus has been a catalyst for change in the pharmacy benefit management industry. Our unique business model is based on the values of integrity and honesty that frame our relationships with our clients. What we have offered our clients from the start—full disclosure, program control and aligned objectives—is now becoming the business model of choice. Our business model provides full disclosure and is transparent, with no fees or competing hidden business relationships. Consistent with our mission and values, Argus’ programs are fully auditable. Argus is free from industry bias and conflicts of interest—and has been recognized as an industry leader in these areas. Argus does not compete with our customers for business, act as a plan sponsor, nor do we own or have ownership in a mail order distribution facility. By not owning or operating a mail-service pharmacy, we have no reason to give advice regarding plan design that is biased toward a mail-service benefit. Such independence gives us the opportunity to be a leader in a fully transparent pharmacy benefit model for our customers and further the cause for industry transparency, reducing costs, and providing quality care.

    Astellas Pharma US, Inc. http://www.us.astellas.com/
    Chelsea Glinski
    Associate Director Health Systems Operations
    (224) 205-8658
    chelsea.glinski@astellas.com

    Launched in April 2005, Astellas was formed by the historical merger of Japan’s third and fifth largest pharmaceutical companies- Yamanouchi, founded in 1923, and Fujisawa, founded in 1894. Created from a partnership of two respected, leading global companies, Astellas is built on a strategic platform focused in select therapeutic areas: Cardiology, Dermatology, Immunology, Infectious Disease, Oncology and Urology. Within each therapeutic area, Astellas focuses on unsurpassed science and building networks of trust among physicians, patients and partners. Key strategic products include: Prograf, VESIcare, Lexiscan, Adenoscan, Protopic, Amevive, AmBisome and Mycamine.

    Auxilium Pharmaceuticals, Inc. http://www.auxilium.com
    Betty Jean M. Swartz
    Vice President Managed Care & Reimbursement
    (484) 321-2095
    bswartz@auxilium.com

    Auxilium Pharmaceuticals (NASDAQ: AUXL) was founded in 1999 to develop and market pharmaceutical products that focus on urology and sexual health. While we remain dedicated to this founding principle, Auxilium’s mission has expanded to include the development and marketing of novel treatment options for many of society’s unmet medical needs. To support this mission of providing innovative solutions that promote healthy living, Auxilium is: • providing healthcare specialists with quality products and practice support • building on its development capability to deliver high-quality products for a range of unmet health needs • pursuing licensing opportunities for additional products that complement its mission and development portfolio • exploring business development and partnership opportunities

    Baxter Healthcare Corp http://www.baxter.com
    Royal Stewart
    Group Director, Payor Accounts
    (800) 777-5513 x7017
    royal_stewart@baxter.com

    Baxter International Inc. (NYSE:BAX), through its subsidiaries, develops, manufactures and markets products that save and sustain the lives of people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. As a global, diversified healthcare company, Baxter applies a unique combination of expertise in medical devices, pharmaceuticals and biotechnology to create products that advance patient care worldwide. Baxter had 2009 sales of $12.6 billion and has approximately 49,700 employees.

    Danelle Caldwell
    Key Account Manager
    (248) 650-8411
    danelle.caldwell@bayer.com

    From world-renowned pharmaceutical products to high-tech platforms, from innovative diagnostics technologies to veterinary medicines – Bayer HealthCare is a globally researching healthcare company.

    Biogen Idec, Inc. http://www.biogenidec.com
    Christine List
    Sr. Director, Health Care Systems Marketing
    (781) 464-5557
    christine.list@biogenidec.com

    Biogen Idec creates new standards of care in oncology, immunology, and neurology. As a global leader in the development, manufacturing and commercialization of novel therapies, Biogen Idec transforms scientific discoveries into advances in human healthcare. For press releases and additional information about the company, please visit www.biogenidec.com.

    Michael J. Baldzicki
    Vice President
    (614) 668-7194
    mbaldzicki@gmail.com

    Founded in 2004, BioRx is a national provider of specialty pharmacy, infusion management and industry consulting services. As a private, independently-owned company, BioRx is committed to a flexible service model that meets the needs of its customers, including consumers, healthcare providers, health plans and pharmaceutical manufacturers.

    Boehringer Ingelheim Pharmaceuticals, Inc. http://www.boehringer-ingelheim.com
    Michael Harry Neufeld
    Associate Director, Managed Markets Marketing
    (630) 717-9064
    michael.neufeld@boehringer-ingelheim.com

    The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine. As a central element of its culture, Boehringer Ingelheim has a demonstrated commitment to corporate social responsibility. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors. In 2011, Boehringer Ingelheim achieved net sales of about $17.1 billion (13.2 billion euro). R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales. For more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at http://twitter.com/boehringerus.

    Bristol-Myers Squibb Company http://www.bms.com
    Desiree Gendron
    Regional Director, Marketing Access East
    (918) 550-1605
    desiree.gendron@bms.com

    Our company’s mission is to extend and enhance human life by providing the highest-quality pharmaceutical and related health care products. We pledge – to our patients and customers, to our employees and partners, to our shareholders and neighbors, and to the world we serve – to act on our belief that the priceless ingredient of every product is the honor and integrity of its maker. Aligned with our mission, Bristol-Myers Squibb Managed Markets team is dedicated to supporting the important role managed care plays in extending and enhancing human life.

    David Calabrese
    VP, Clinical Services & Chief Pharmacy Officer
    (508) 926-1314
    David.calabrese@catamaranrx.com

    Catalyst Health Solutions, Inc., the fastest growing national PBM in the U.S., is built on strong, innovative principles in the management of prescription drug benefits and provides an unbiased, client-centered philosophy resulting in industry-leading client retention rates. The Company's subsidiaries include Catalyst Rx, a full-service pharmacy benefit manager (PBM) serving more than 18 million lives in the United States and Puerto Rico; HospiScript Services, LLC, one of the largest providers of PBM services to the hospice industry; FutureScripts, LLC, a full-service PBM serving approximately one million lives in the mid-Atlantic region; and a fully integrated prescription mail service facility. The Company's clients include self-insured employers, including state and local governments, managed care organizations, unions, hospices, third-party administrators and individuals.

    CECity.com, Inc. http://www.cecity.com
    Annette D. Boyer
    Vice President, Business Development
    (412) 586-3312
    aboyer@cecity.com

    CECity (www.cecity.com) is the health care industry's leading cloud-based provider of social enterprise platforms and services that address the "3 Ps" driven by healthcare reform: Pay for Value Reporting, Performance Improvement, and Professional Certification. CECity combines its unique registry and analytics platform with education and improvement interventions from world-class partners, to help all stakeholders answer the most important question, "How Do We Improve?" Leading organizations across healthcare, including national pharmacy organizations, ACOs, health systems, health plans, pharmacies, physician practices, certifying boards, professional societies and academic medical centers, count on CECity to power their high stake solutions for practice-based learning and performance improvement, registries, professional development, maintenance of certification, medication adherence, care coordination, population health management and value-based reporting. In addition, CECity, along with the Pharmacy Quality Alliance (PQA), launched Pharmacy Quality Solutions, Inc. (PQS), a joint venture created to deliver EQuIPP™ (Electronic Quality Improvement Platform for Plans and Pharmacies). EQuIPP™ is the first national pharmacy quality measurement, benchmarking, and reporting platform for pharmacies and health plans. EQuIPP™ measures the quality of patient medication use, including non-adherence. EQuIPP™ enables pharmacies and health plans to focus on improving the quality and safety of patient care delivered.

    Celgene Corporation http://www.celgene.com
    George Malouly
    National Accounts
    (310) 995-0175
    gmalouly@celgene.com

    Celgene is a global integrated biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies designed to treat cancer and immunoinflammatory diseases. Celgene is dedicated to work closely with health care providers to assure patients in need have safe access to our drugs. The Company is also proud of the important benefits that our therapies bring to patients, of the Company’s demonstrated commitment to rapidly advance its promising new therapies through development so many more patients can be helped, and of the breadth of its programs to ensure that no American is denied access as a result of lack of resources. The ongoing development of our broad and deep proprietary pipeline of immunomodulatory agents (IMiDs®), cell-signaling inhibitors, as well as cellular and tissue therapeutics may allow Celgene to provide physicians worldwide with a more comprehensive and integrated set of therapeutic solutions for managing complex human diseases.

    Celldex Therapeutics http://www.celldex.com
    Reg Waldeck
    Sr. Director, Market Access
    (908) 200-7550
    rwaldeck@celldex.com

    Celldex Therapeutics (NASDAQ: CLDX) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. The Company’s pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers—including many underserved or completely un-served orphan indications. This has created a leading pipeline in immunotherapy comprised of two candidates in pivotal trials, one in brain cancer and one in triple negative breast cancer, four additional clinical candidates in a range of difficult-to-treat indications and a robust preclinical engine.

    Cottrill's Pharmacy, Inc. http://www.cottrillspharmacy.com
    Thomas J. Nuttle
    VP Business Development
    (716) 508-8481
    t.nuttle@cottrillspharmacy.com

    Privately owned, Cottrill’s Pharmacy offers decades of experience in bleeding disorders through its employees located around the country. Our care management model places patients and their families at the center of everything we do. This allows us to offer payors and employers creative solutions to help mitigate medical complications and added financial risk.

    CSI Specialty Group http://www.csigroup.net
    Suzette Dimascio
    President and CEO
    (407) 688-6727
    suzette@csigroup.net

    CSI Specialty Group is a Globally Recognized Consulting, Work Force Planning & Talent Acquisition firm that helps clients create the right processes to drive Accelerated Growth for Specialty Pharmacy, Manufacturers/Biotech, Mail Order/PBM & Health Systems/Health Plans Worldwide. As the Industry’s Most Influential Leader in Specialty Pharmacy Consulting and Talent Acquisition, CSI Specialty Group delivers consulting solutions and talent resources to help clients cultivate excellence through uniquely linking their business strategy to their people strategy – ultimately unlocking talent as a true competitive differentiator/advantage. CSI is uniquely positioned to provide companies with the insight, industry expertise and the people who will contribute to the corporate goals and make a real impact on the organization. Leverage the CSI Specialty Group Leadership team’s expertise spanning over 40 years! From Specialty Pharmacy build outs to drug launches. Trust us to create a unique blueprint for your success.

    Gary A. Loeber
    Principal
    (847) 559-3817
    gary.loeber@caremark.com

    CVS Caremark is the largest provider of prescriptions in the nation. The Company fills or manages more than 1 billion prescriptions annually. Through its unmatched breadth of service offerings, CVS Caremark is transforming the delivery of health care services in the U.S. The Company is uniquely positioned to effectively manage costs and improve health care outcomes through its more than 6,900 CVS/pharmacy and Longs Drugs stores; its Caremark Pharmacy Services division (pharmacy benefit management, mail order and specialty pharmacy); its retail-based health clinic subsidiary, MinuteClinic; and its online pharmacy, CVS.com. General information about CVS Caremark is available through the Investor Relations section of the Company's Web site, at www.cvscaremark.com/investors, as well as through the press room section of the Company's Web site, at www.cvscaremark.com/newsroom.

    Daiichi Sankyo, Inc. http://www.dsi.com
    Anwell Wilbekin
    Director, Regional Accounts - Northeast
    (508) 925-5586
    awilbekin@dsi.com

    Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Japan-based Daiichi Sankyo Co., Ltd., one of the twenty largest pharmaceutical companies in the world and a global leader in pharmaceutical innovation since 1899. The company is dedicated to the discovery, development and commercialization of innovative medicines that improve the lives of patients throughout the world. The primary focus of Daiichi Sankyo’s research and development is cardiovascular disease, including therapies for dyslipidemia, hypertension, diabetes, and acute coronary syndrome. The company is also pursuing the discovery of new medicines in the areas of glucose metabolic disorders, infectious diseases, cancer, bone and joint diseases, and immune disorders. For more information, visit www.dsus.com.

    David J. Martin
    Vice President of Managed Markets, Value & Access Group
    (201) 746-2720
    david_martin@eisai.com

    Eisai Inc. is supported by a strong parent company, Eisai Co., Ltd., which was founded in Japan in 1941 as Nihon Eisai Co., Ltd. To this day, Eisai Co., Ltd. is one of the few Japanese pharmaceutical companies to undertake aggressive global expansion through substantial infrastructure investments in its foreign affiliates. These affiliates conduct research and development, manufacturing, and sales and marketing in the United States, Europe and Asia. Globally, most of Eisai’s sales are derived from treatments for central nervous system diseases and gastrointestinal disorders. Eisai has more than 7,000 employees worldwide and is a publicly traded company whose stock trades on the Tokyo and Osaka exchanges and in the United States under an American Depository Receipt with the ticker symbol of ESALY.

    EMD Serono Inc. http://www.emdserono.com
    Allene Diaz
    Senior VP, Managed Markets
    (781) 681-2882
    allene.diaz@emdserono.com

    EMD Serono, Inc. is committed to discovering and developing medicines that address unmet medical needs. EMD Serono focuses its business in the areas of neurology, reproductive health, metabolic endocrinology, oncology, and autoimmune disease, integrating innovative science with comprehensive patient support systems to improve lives. Visit us at www.emdserono.com.

    Jody H. Allen
    VP, Clinical Account Management, Health Plans
    (804) 967-7122
    jody_allen@express-scripts.com

    At Express Scripts, we help make the use of prescription drugs safer and more affordable. It's been our mission since 1986, when a group of healthcare advocates began applying the rigors of scientific research to the pharmacy benefit. With the country facing hundreds of billions of dollars of prescription-related waste each year from costly drug, pharmacy and health choices, our mission remains as relevant as ever. We are passionate about gleaning insights from data and translating those insights into solutions. We test and learn our way toward the most comprehensive set of solutions to drive out prescription-related waste and help improve health outcomes. We provide best-in-class pharmacy benefit management (PBM) services and industry-leading home delivery and specialty pharmacy services for our diverse client base.

    First Report - Managed Care http://www.hmpcommunications.com
    Christopher Ciraulo
    Vice President & Group Publisher
    (610) 560-0500 x311
    cciraulo@hmpcommunications.com

    First Report® Managed Care (firstreportnow.com) is a managed markets print and online brand that circulates to more than 21,000 health plan CEOs, hospital formulary committee members, HMO pharmacists, health plan medical directors and pharmacy directors, large employer decision-makers, and state prison facility managers. The editorial mission is focused on delivering the most comprehensive late-breaking information that affects managed market providers with topics that include clinical, legislative, and economic developments. First Report Managed Care also reports on dozens of scientific and managed care conferences throughout the world, providing readers with pertinent news from scientific sessions, symposia, and late-breaking clinical trials. In addition, the First Report Managed Care award-winning travel brand is the official City Guide of both the AMCP Annual Meeting and Educational Conference.

    Forest Laboratories, Inc. http://www.frx.com
    Mark Devlin
    Senior Vice President, Managed Markets, Government & Policy
    (212) 224-6625
    mark.devlin@frx.com

    Forest Laboratories (NYSE: FRX) is a U.S.-based pharmaceutical company with a long track record of building partnerships and developing and marketing products that make a positive difference in people’s lives. In addition, to its well-established franchises in therapeutic areas of the central nervous and cardiovascular systems, Forest’s current pipeline includes product candidates in all stages of development and across a wide range of therapeutic areas. The company is headquartered in New York, NY. To learn more about Forest Laboratories, visit www.FRX.com.

    Fresenius Medical Care North America http://www.fmcna.com
    Ausrine Williams

    (781) 699-4527
    ausrine.williams@fmc-na.com

    Providing direct renal services to over 167,000 ESRD patients, Fresenius Medical Care (FMCNA) is the largest provider of renal therapy services and products in the United States. We manufacture and distribute the leading dialysis products and equipment and other dialysis_related supplies. Fresenius Medical Cared North Americas pharmaceutical offering includes, Velphor®, Venofer® & Phoslyra®.

    Genentech, Inc. http://www.gene.com
    Shannon Paley
    Field Operations & Communications
    (650) 225-4895
    shannono@gene.com

    Genentech, Inc. is a leading biotechnology company focusing on the discovery, development, manufacture, and marketing of pharmaceuticals for significant, unmet medical needs. Genentech’s managed care specialists are committed to enhancing the quality and delivery of patient care by working with managed care organizations to find effective solutions to health care issues.

    Gilead Sciences, Inc. http://www.gilead.com
    Bruce Pfaff
    Director, Market Access
    (650) 522-5123
    bruce.pfaff@gilead.com

    Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia. Visit Gilead on the World Wide Web at www.gilead.com.

    GlaxoSmithKline http://www.gsk.com
    Mark Santry
    Director, Professional Relations
    (919) 483-7508
    mark.j.santry@gsk.com

    GlaxoSmithKline (GSK), one of the world’s leading research-based health care companies, discovers, develops, manufactures and markets pharmaceuticals, vaccines, over-the-counter medications and health-related products. GSK’s people are committed to fighting disease by bringing innovative medicines and services to patients throughout the world and to the health care providers who serve them.

    HAVAS Worldwide Health http://www.havashealth.com/
    Khawar Khokhar
    Head of Market Access/B2B
    (860) 680-0836
    khawar.khokhar@havashealth.com

    Managed Edge, a Havas Health Company Managed Edge creates innovative market access business solutions that give client partners a competitive edge. Managed Edge provides unbeatable client support in communicating product value to formulary decision-makers in order to maximize reimbursement. Core competencies include integrated market access strategy, formulary access and pull-through, including account manager sales tools, expanded market reach, care and disease management, provider and MCO education, and market access training, as well as health economics and outcomes research. To further support promotional programs to and through market access customers, Managed Edge also delivers symposia, dinner meetings, teleconferences, CDROMs, slide kits, publication planning, and print materials that offer comprehensive initiatives designed to motivate and educate healthcare stakeholders. Managed Edge is a strategic marketing and consulting firm within Havas Health. Havas Health is a group of strategically integrated healthcare communications companies providing advertising, marketing services, corporate communications, interactive solutions, and strategic consulting tailored to healthcare and wellness clients.

    Health Information Designs, Inc. http://www.hidllc.com
    Kathleen Sabo
    Director of Business Development & Marketing
    (334) 466-3031
    kathleen.sabo@hidllc.com

    Health Information Designs (HID) is a pharmacy services company that provides a comprehensive suite of prior authorization (PA) solutions to health plans and pharmacy benefit managers for promoting compliance monitoring, adherence, and criteria management. HID's clinical professionals?pharmacists, physicians, and nurses?know the industry, our products, and our clients. Our combined total of over 650 years of pharmacy experience provides the strong clinical foundation on which we build our solutions.

    Larry Blandford
    Executive Vice President, Managing Partner
    (908) 470-1780
    lblandford@hobartinnovations.com

    Hobart Group Holdings is the leading marketing and consulting firm in the United States that provides relevant and innovative solutions that connect life science companies and purchasers to support value-based outcomes. Founded in May 2003, Hobart is a consortium of full-service, thought-leader agencies focused solely on managed health care: The Hobart Group, Hobart Forte, and Hobart Core, as well as a separate research company, Hobart Innovations. Each company delivers a variety of services to a large client base through unrivaled strategic executive teams, innovative capabilities, and customized solutions. Our capabilities include advertising and promotion, meetings, market research, HEOR, sales training, digital production, and contracting and pricing. Hobart's leadership team and staff have more than 100 years of combined experience as pharmacy directors, benefit managers, contracting managers and senior business leaders from MCOs, PBMs, government payers, benefit consultants, health systems, and LTC facilities. Hobart currently is engaged with pharmaceutical and biopharmaceutical companies of all sizes across both key therapeutic areas and critical health care topics. Hobart is one of the fastest growing managed markets agencies in the industry. For more information about Hobart Group Holdings, please visit www.hobartgroupholdings.com.

    Incyte Corporation http://www.incyte.com
    Douglas Kylander
    Director, Access, Reimbursement and Distribution
    (302) 498-5740
    dkylander@incyte.com

    Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary small molecule drugs for oncology and inflammation. Our first commercial product Jakafi® (ruxolitinib), an oral JAK1 and JAK2 inhibitor, was approved by the FDA in November 2011.

    Johnson & Johnson Health Care Companies http://www.jnj.com
    William J. Johnson
    National Account Director
    (847) 726-9962
    wjohnso2@its.jnj.com

    Johnson & Johnson Health Care Companies are committed to creating measurable value for our managed markets customer through a dedicated focus on meeting your needs. In doing so, we will draw on our wide range of innovative products and services. We can work together to improve your clinical and business outcomes.

    Lilly USA, LLC http://www.lilly.com
    John H. Poulin
    Director, Professional Relations
    (317) 277-8173
    jhpoulin@lilly.com

    Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquarted in Indianapolis, IN, Lilly provides answers – through medicines and information – for some of the world’s most urgent medical needs.

    Todd Killian
    Global Vice President, Market Access
    (314) 654-3335
    todd.killian@mallinckrodt.com

    Mallinckrodt is a global specialty pharmaceutical company. Focus areas include therapeutic drugs for autoimmune and rare-disease specialty areas along with analgesics and central nervous system drugs for prescribing by office- and hospital-based physicians. Mallinckrodt’s Specialty Pharmaceuticals segment includes branded and specialty generic drugs and active pharmaceutical ingredients.

    Managed Health Care Associates, Inc. http://www.mhainc.com/
    Alyson Aguanno
    Director of Specialty Program Development
    (973) 805-2940
    AAguanno@mhainc.com

    Managed Health Care Associates, Inc. (MHA) is a leading health care services and technology company focused on the alternate site healthcare provider. MHA provides expertise in Group Purchasing, Managed Care and Payer Contracting, Reimbursement Management, Specialty Pharmacy Solutions, Pharmaceutical Data Analytics, Consultant Pharmacy Software and Legislative Advocacy. Through the delivery of innovative health care services and solutions, MHA helps members increase operational efficiency, maximize business growth and provide optimum care for their patients. Evidence of MHA’s commitment to the specialty market and ongoing investment in development of new programs for pharmacies is MHA Specialty Pharmacy Solutions. MHA Specialty Pharmacy Solutions is dedicated to optimally position specialty pharmacy members to succeed in an increasingly dynamic health care environment. The MHA Specialty Pharmacy Solutions division helps members navigate the complex specialty pharmacy market. We maximize member pharmacies’ opportunities for success by providing access to products, clinical information, and valuable resources that support improved patient outcomes for our member pharmacies while assisting them with data insights and performance reporting requirements. Our experience in strategic contract implementation enables us to align the resources and expertise of our business partners with ever-expanding opportunities across our vast network of member pharmacies. By supplying our partners with data and analytics that report trends and metrics, we support therapy adherence and contract compliance. For more information, visit www.mhainc.com.

    Meda Pharmaceuticals Inc. http://www.medapharma.us
    Jeff Hofmeister
    Senior Director, Managed Care & Trade Relations
    (732) 564-2534
    Jeffrey.hofmeister@meda.us

    Meda Pharmaceuticals is a specialty pharmaceutical company that markets proprietary drugs in allergy and central nervous system therapies. The goal of the managed healthcare account team is to help managed healthcare organizations improve their level of patient care by providing information on the most current products, disease entities, patients, and cost-benefits.

    Rahul D. Singal
    Chief Medical Officer
    (702) 561-8706
    rsingal@medhok.com

    MedHOK (Medical House of Knowledge) is a leader in providing an integrated, cloud-based platform that delivers a quality and compliance solution covering both Rx and Medical care for MCOs and PBMs covering over 22 million lives. For Part D plans, MedHOK electronic Prior Auth integrated with CMS Compliant Appeals, Grievance and CTM is unique in the industry.

    MedImpact Healthcare Systems, Inc. http://www.medimpact.com
    Denise L. Burns
    Vice President, Account Management
    (858) 790-6204
    denise.burns@medimpact.com

    MedImpact Healthcare Systems, Inc. (http://www.medimpact.com), founded in 1989 and headquartered in San Diego, Calif., is a full-service pharmacy benefit management (PBM) company that combines subject matter expertise with innovative technology and services to deliver better healthcare outcomes and improve its clients’ positions in the market. MedImpact provides PBM services to 47 million members of health plans, hospitals and employers in the U.S. and abroad. MedImpact’s model is unique: avoiding conflict of interest by deriving revenue from effectively managing client pharmacy benefits rather than dispensing drugs.

    Merck & Co., Inc. http://www.merck.com
    Sandra M. Reiss
    Customer&Payer Brand Strategy/MarketingManaged Care Sales & Marketing
    (267) 305-8185
    sandra.reiss@merck.com

    Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work wtih customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com.

    Merz Pharmaceuticals, LLC http://www.merzusa.com
    Douglas R. Matter
    National Account Director
    (480) 559-2174
    douglas.matter@merz.com

    Merz North America is a specialty healthcare company that develops and commercializes innovative treatment solutions in aesthetics, dermatology and neurology in the U.S. and Canada. Our ambition is to become a recognized leader in the treatment of movement disorders, and in aesthetics and dermatology. Our future is promising, and we are committed to advancing new therapeutic options and improving patients’ lives. For more than 100 years, the development of our products has been based on Merz‘s commitment to providing innovative medical approaches that earn trust of patients, physicians and partners worldwide. Globally, the companies of Merz Pharma Group are focused on medications for treating neurological and psychiatric illnesses, and they have assumed a leading role in the field of Alzheimer’s disease research. Founded in 1908, Merz Pharma Group is a privately owned company headquartered in Frankfurt, Germany.

    Nicole Willing
    Regional Account Manager
    (908) 543-2038
    nicole.willing@mylan.com

    Mylan is one of the world’s leading generics and specialty pharmaceutical companies, providing products to customers in more than 150 countries and territories. The company maintains one of the industry’s broadest and highest quality product portfolios, which is regularly bolstered by an innovative and robust product pipeline.

    Kristie Raker
    Director, Professional Association Relations
    (609) 786-4595
    ksra@novonordisk.com

    Novo Nordisk Inc. is a focused healthcare company. With a broad diabetes product portfolio, including innovative products within the area of insulin delivery systems, Novo Nordisk is a world leader in diabetes care. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession, and society. Worldwide, Novo Nordisk employs an estimated 18,800 people in 69 countries and markets its products in 179 countries. Novo Nordisk's global headquarters is located in Denmark where the company began more than 80 years ago with the North American affiliate headquartered in Princeton, NJ.

    Onyx Pharmaceuticals http://www.onyx.com
    Dean Masztak
    Market Access Manager
    (269) 568-0492
    menko806@yahoo.com

    Based in South San Francisco, California, Onyx Pharmaceuticals is a subsidiary of Amgen, engaged in the development and commercialization of innovative therapies for improving the lives of people with cancer. At Onyx, we are grounded in three leadership hallmarks that guide how we manage our business and build value for patients and shareholders: innovation, patient-centeredness and stewardship.

    Samir K. Mistry
    Pharmacy Practice Leader
    (612) 819-6680
    skmistry@yahoo.com

    In the world of successful business, change is a constant. Optimity Advisors manages and delivers complex business change reliably with deep industry knowledge, information technology, strategic planning, business process re-engineering, organizational change management, and risk mitigation services. We are an operational consultancy that develops fact-based solutions to help transform your business.

    Brand Newland

    (515) 864-7944
    bnewland@outcomesmtm.com

    Founded in 1999, OutcomesMTM is the national leader in Medication Therapy Management, delivering a cost-effective approach to advancing patient care and utilization control, and providing patient-friendly Personal Pharmacist™ services that demonstrate the Face-to-Face Difference™. The company is headquartered in West Des Moines, Iowa.

    John C. Butts
    Director, Sales and Public Relations
    (215) 937-8073
    john.butts@performrx.com

    PerformRx, LLC provides innovative, cost-effective pharmacy benefit management services for Medicaid, Medicare, and commercial health plans. Through a distinctive, hightouch approach, PerformRx partners with health plans to improve patient outcomes and financial performance. PerformRx bases its success on a clinical focus hat is driven by cuttingedge, proprietary technology.

    John W. Main
    Senior Director Field Based Medical
    (630) 634-3648
    john.main@pfizer.com

    As one of the world’s leading healthcare companies, Pfizer has developed and brought to market medicines for humans and animals for over 150 years. Our portfolio includes more category-leading medicines than any other company – treatments that are helping countless people everyday to ease arthritis and nerve pain, manage depression, fight diabetes and cancer and control hypertension. Our portfolio of innovative medicines currently includes treatments for more than a dozen disease areas and we are targeting unmet medical needs through state-of-the-art research and development. We know that healthcare is more than a business—it’s a mission-and our products can only help people if they can get them. That’s why we are deeply committed to enhancing access to high-quality healthcare. This year, through innovative partnership programs, Pfizer is giving product donations for patients in need around the world and building the infrastructure necessary to ensure that the medicines get to those who need it most. The value of medicine. The benefits of research. The commitment to help meet the needs of those in need. At Pfizer, we dedicate ourselves to humanity’s quest for longer, healthier, happier lives through innovation in pharmaceutical, consumer and animal health products.

    Mark Connors
    CEO
    (617) 489-8700
    mark@pleio.com

    Pleio, Inc., is a leader in patient engagement and medication adherence, where real people talk to real patients. Our patient-centric offerings integrate each stakeholder in the ecosystem by applying proven behavior shaping programs specific to disease states and drug classes. Our results are measured through increased medication adherence, higher PDC scores and improved health plan STAR ratings. We support our trading partners’ strategies by meeting each patient where they are in their wellness journey. The combined use of people to make a personal connection through live calls, and technology to measure results sets us apart. Our partners include health plans, PBMs, drug manufacturers, pharmacists/pharmacies, pharmacy system vendors, and medical professionals.

    Professional Compounding Centers of America (PCCA) http://www.pccarx.com/
    Del Doherty
    Director, Managed Care Services
    (800) 331-2498
    ddoherty@pccarx.com

    PCCA has become the independent compounding pharmacist’s complete resource for fine chemicals, equipment, devices, flavors, ACPE-accredited training and education, pharmacy software, marketing, business and pharmacy consulting assistance. Our membership includes more than 3,900 independent community pharmacists in the United States, Canada, Australia, and other countries around the world. PCCA’s mission is to strengthen the role, position and skills of member compounding pharmacists so they can meet the unique healthcare needs of patients through our exceptional service, highest-quality products, shared innovations and education.

    Purdue Pharma, L.P. http://www.pharma.com
    Craig Engesser
    Associate Director, Healthcare Alliance Development
    (203) 588-8000
    craig.engesser@pharma.com

    Purdue Pharma L.P. is well known for its pioneering work on persistent pain, a principal cause of human suffering. The company’s leadership and employees are dedicated to providing healthcare professionals, patients and caregivers with effective therapies, and innovative educational resources and tools that support their proper use.

    Ravi Ika
    President & CEO
    (508) 804-6900
    ravi.ika@rxadvance.com

    RxAdvance is a national full service PBM (Pharmacy Benefit Manager), bringing superior clinical, pharmacy, and financial outcomes to plan sponsors through Collaborative PBM Cloud. Built on a unified data model and clinical intelligence, RxAdvance’s PBM standard services include Benefit and Formulary Design, Claims Processing, Customer Support Services, Retail Pharmacy Network Management, Clinical Services, and Rebate Management. Our market differentiation includes Drug Utilization Review at Point of Care (PoC) and Point of Sale (PoS), Medication Therapy (MTM) and Adherence Management (MAM), Donut Hole Prediction and Prescription Planner, Optimize Untapped Generics Usage, Prevent Adverse Drug Effects, Fraud, Waste and Abuse Management, Advanced Analytics and Cost Management, Maximize Mail Order Services, and Effective Specialty Management. RxAdvance enables real-time actionable communication between prescriber, pharmacist, patient, and payer. Our best in class People, Process and Technology are for all plan sponsors—health plans, Accountable Care Organizations (ACOs), state Medicaid programs, employer groups, and unions. We provide contractually guaranteed savings in administrative costs, unit costs, and rebate revenues.

    Salix Pharmaceuticals, Inc. http://www.salix.com
    John D. Temperato
    Sr Vice President, Managed Markets & Sales
    (919) 862-1086
    john.temperato@salix.com

    Salix Pharmaceuticals is dedicated to being the leading specialty pharmaceutical company providing products to Gastroenterologists and their patients.

    James Caro
    Senior Director, US Advocacy
    (202) 585-3030
    james.caro@sanofi-aventis.com

    Sanofi-Aventis, a leading global pharmaceutical company, discovers, develops, and distributes therapeutic solutions to address the world’s expanding healthcare needs. We work to prevent and treat the diseases that we know of today, as well as those we may face tomorrow. With approximately 100,000 dedicated professionals in more than 100 countries, Sanofi-aventis is devoted to advancing healthcare around the world. We are committed to maintaining the innovative approach to pharmaceuticals established by our parent company, headquartered in Paris, France. Our U.S. affiliate, with headquarters in Bridgewater, New Jersey, employs approximately 12,000 professionals located throughout the country. Sanofi-aventis, U.S. is a dynamic healthcare organization working to meet the needs of physicians and their patients. At sanofi-aventis, each and every day we work for what really matters: health .For more information, visit www.sanofi-aventis.us

    Shire US Inc. http://www.shire.com
    Joseph G. Stahl
    VP, Head of US Value Strategy
    (484) 595-8806
    josephstahl@yahoo.com

    Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results. For further information on Shire, please visit the Company’s website: www.shire.com.

    Sunovion Pharmaceuticals, Inc. http://www.sunovion.com
    Melissa Longstreet Kay
    Associate Director, Managed Markets Marketing
    (508) 357-7710
    melissa.longstreet-kay@sunovion.com

    We are Sepracor, a research-based pharmaceutical company with a focus on treatments for respiratory and central nervous system. Our robust product pipeline is focused on providing treatments that address large and growing disease states that are principally served by primary care physicians. From insomnia to asthma, to depression and restless legs syndrome, we are seeking ways to improve the lives of the millions of people suffering from these potentially debilitating conditions. The Sepracor Organized Customer Group is dedicated to working with managed care executives to find innovative solutions to improve patient care and support efforts to provide quality health care. The common stock of Sepracor Inc. is traded on the NASDAQ Stock Market under the symbol SEPR.

    Supernus Pharmaceuticals Inc http://www.supernus.com
    Gary Ellexson
    VP, Corporate Accounts
    (301) 838-2557
    gellexson@supernus.com

    With more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) disorders. We are developing several product candidates in neurology and psychiatry to address unmet medical needs and opportunities in epilepsy, attention-deficit hyperactivity disorder (ADHD) and its coexisting disorders, and depression. We are developing differentiated products by leveraging our proprietary and in-licensed technologies. We use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. Our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.

    Takeda Pharmaceuticals U.S.A., Inc. http://www.tpna.com
    Kathy Shannon
    Cross-Brand Relationship Marketing Manager - Managed Markets/Trade
    (224) 554-7733
    katherine.shannon@takeda.com

    Based in Deerfield, Ill., Takeda Pharmaceuticals North America, Inc and Takeda Global Research & Development Center, Inc are subsidiaries of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. The respective companies currently market oral diabetes, insomnia, rheumatology, gastroenterology, and cardiovascular treatments and seek to bring innovative products to patients through a pipeline that includes compounds in development for metabolic and cardiovascular disease, gastroenterology, neurology and other conditions. To learn more about Takeda companies, visit www.tpna.com.

    Teva Pharmaceuticals http://www.tevapharm-na.com
    Michael B. Pursel
    Head of US Medical Advocacy, US Medical Affairs
    (913) 777-3072
    mike.pursel@tevapharm.com

    Teva Pharmaceuticals’ North America Brand Pharmaceuticals group is built on the knowledge and expertise of multiple innovative business units, including respiratory, neurology, women’s health and biologics/specialty products. This brand division leverages the skills and competencies of each therapeutic area, and coordinates and aligns efforts for a more efficient and effective delivery of healthcare solutions.

    Seth Gordon
    Managing Partner
    (973) 255-9360
    sgordon@theaccessgp.com

    The Access Group is the leading independent strategic health care communications network composed of 8 distinct companies: Access Alliance, Access Communications, Catalyst, Fusion Medical Communications, MedAccess, Promidian, S3 – Strategic Selling Solutions, and StrataMed. The firm employs more than 85 health care marketing specialists and senior leaders with experience in management consulting, medical education, marketing communications, managed markets, training, and brand promotion. The Access Group is headquartered in Berkeley Heights, New Jersey, with offices in New York City, Chicago, San Diego, and San Francisco. To learn more about our firm, please visit www.theaccessgp.com or contact Dave Gagliano, President and CEO, at (908) 508-6700.

    Thrombogenics, Inc. http://www.thrombogenics.com
    Kevin Clarke
    US Head of Market Access & Reimbursement
    (732) 232-2366
    kevin.clarke@thrombogenics.com

    ThromboGenics is a biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines. The company’s lead product is ocriplasmin (Jetrea) has been approved by the FDA for the pharmacological treatment of symptomatic Vitreomacular Adhesion (VMA).

    Upsher-Smith Laboratories, Inc. http://www.upsher-smith.com
    Mike McBride
    AVP, Partner Relations
    (763) 315-2713
    mike.mcbride@upsher-smith.com

    Upsher-Smith is dedicated to the pursuit of innovative products that enable people to live life to its greatest potential. The evolution of our company is driven by a spirit of collaboration, passion, and the shared goal of making life moments matter for the people who rely on us and our therapies. Our world is constantly evolving, and we are continually adapting to the ever-changing needs of patients, physicians, pharmacists, and healthcare organizations. As these needs grow, so do we. That’s why we are actively exploring product opportunities in the areas of the central nervous system, women’s health, dermatology, and generics. Where there is a need, we will strive to find a solution.

    Jon Magness
    Clinical Pharmacy MTM Manager
    (801) 433-6230
    jmagness@myvrx.com

    Veridicus Health provides comprehensive and customizable pharmacy solutions. We are industry leaders in clinical care management, MTM and PBM services for commercial and Medicare Part D Plans. Veridicus means Speaking Truth. Speaking Truth is our corporate philosophy and exemplifies the type of honest and complete information you will always receive from us. We are committed to providing exemplary service while maintaining lowest net cost. We focus on integrating auxiliary health care services into one cohesive solution, empowering members to make informed decisions regarding their healthcare, and easing your administrative burden.

    Sunil Karnawat
    Director, Managed Care
    (650) 934-5200
    karnawat@vivus.com

    VIVUS, Inc. is a biopharmaceutical company dedicated to the development and commercialization of novel therapeutic products addressing obesity, diabetes, sleep apnea and sexual health.

    Danette Colleen Stephens
    Senior Director
    (303) 884-3383
    Ldss1@msn.com

    WellDyneRx is an innovative, full-service prescription benefit manager, servicing its health plan members through a retail network of over 65,000 pharmacies nationwide. Our full-service mail order facilities utilize advanced robotics to accurately fill more than 1 million prescriptions per year.

    Matthew J. McCarville
    VP, Managed Markets
    (858) 436-3375
    matthew.mccarville@gmail.com

    Zogenix is committed to developing therapies that address specific clinical needs for people living with CNS and pain-related conditions who need innovative treatment alternatives to help them return to normal daily functioning.

    Content for class "break" Goes Here